Source-grounded facts extracted from TuHURA Biosciences, Inc./NV's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
TuHURA Biosciences, Inc./NV reported the three months ended September 30, 2022 results: net income net loss of approximately $4.6 million, or $0.07 per share, EPS $0.07 per share.
“For the three months ended September 30, 2022, Kintara reported a net loss of approximately $4.6 million, or $0.07 per share, compared to a net loss of approximately $6.0 million, or $0.25 per share, for the three months ended September 30, 2021.”
Saiid Zarrabian departed as Head of Strategic Partnerships and Director at TuHURA Biosciences, Inc./NV.
“On May 20, 2022, Kintara Therapeutics, Inc. (the “Company”) and Saiid Zarrabian, the Company’s Head of Strategic Partnerships and a member of the Board of Directors (the “Board”) of the Company, mutually agreed that Mr. Zarrabian would step down from his role as Head of Strategic Partnerships and as a member of the Board, effective as of May 23, 2022 (the “Separation Date”) to pursue other opportunities.”
Keith Murphy resigned as Director at TuHURA Biosciences, Inc./NV.
“On February 4, 2022, Keith Murphy submitted his resignation from the Board of Directors (the “Board”) of Kintara Therapeutics, Inc. (the “Company”), effective immediately.”
Saiid Zarrabian changed role as Head of Strategic Partnerships at TuHURA Biosciences, Inc./NV.
“on November 8, 2021, the Board and Mr. Zarrabian mutually agreed that Mr. Zarrabian would immediately transition into the role of Head of Strategic Partnerships.”
Robert E. Hoffman was appointed as President and Chief Executive Officer at TuHURA Biosciences, Inc./NV.
“On November 8, 2021, the Board of Directors (the “Board”) of Kintara Therapeutics, Inc. (the “Company”) appointed Robert E. Hoffman, the then current Chairman of the Board, to succeed Saiid Zarrabian as President and Chief Executive Officer of the Company.”
John Liatos resigned as Senior Vice President, Business Development at TuHURA Biosciences, Inc./NV.
“On October 25, 2021, Kintara Therapeutics, Inc. (the “Company”) and John Liatos, the Company’s Senior Vice President, Business Development, mutually agreed that Mr. Liatos would step down from his role as Senior Vice President, Business Development effective immediately to pursue other opportunities.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.